Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2025 and 2026.
Financials
Financial year 2026
ADx NeuroSciences from Gent, company number BE0839400980, closed financial year 2026 with a result of € -380,057 after tax. For that financial year ADx NeuroSciences recorded a gross margin of € 1.6 million and equity of € 4.2 million. Compared with financial year 2025, the result moved from € -525,119 to € -380,057. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 4.2 million
▼ 8% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -380,057
▲ 28 % less loss than in 2025
Profit after tax over the fiscal year.
€ 223,675
▼ 46% vs 2025
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -992,519.
People and assets in 2026
18.8
▲ 2.3 vs 2025
Average over the fiscal year, from the social balance sheet.
€ 1.8 million
▲ 15% vs 2025
€ 94,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 14,199
▼ 26% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
€ 70,293
▼ 91% vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 414,765
▲ 9% vs 2025
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 2,977,550 | € 2,637,225 | € 911,748 | € 1,617,141 | ▲ 77% |
| Profit after taxes | € 1,384,756 | € 1,255,427 | € -525,119 | € -380,057 | ▲ € 145,061 |
| Equity | € 3,867,030 | € 5,122,457 | € 4,597,339 | € 4,217,281 | ▼ 8% |
| Total debts | € 847,483 | € 712,441 | € 1,267,373 | € 661,069 | ▼ 48% |
| Cash | € 411,661 | € 389,016 | € 414,156 | € 223,675 | ▼ 46% |
| Retained profit | € -1,342,770 | € -87,343 | € -612,461 | € -992,519 | ▼ € 380,057 |
| Bank debt | € 3,528 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 4,714,513 | € 5,834,898 | € 5,864,712 | € 4,878,350 | ▼ 17% |
| Employees (FTE) | 14.7 | 15.7 | 16.5 | 18.8 | ▲ 2.3 |
Key figures of ADx NeuroSciences, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to ADx NeuroSciences?
What happened at ADx NeuroSciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: loss of € 380,057. Source: NBB ↗
- KDIV Consult stepped down as director. NBB
- Goki Ishikawa stepped down as director. NBB
- Tadashi Ninomiya became a director. NBB
- Kurt Troch became a director. NBB
- Koji Aoki became a director. NBB
- CDW Invest became a director. NBB
- Goki Ishikawa became a director. NBB
In short
From € 1.4 million profit in 2023 to € 380,057 loss in 2026.
Paid € 77,885 in corporate taxes since 2023.
Best year ever: 2023, with € 1.4 million profit.
On average € 86,000 of value added per employee in 2026.
A new publication or filing at ADx NeuroSciences? We notify you, reason included.
Follow ADx NeuroSciencesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of FUJIREBIO EUROPE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ADx NeuroSciencesBehind ADx NeuroSciences are Tadashi Ninomiya, Kurt Troch, Koji Aoki and CDW Invest. The shares are held by FUJIREBIO EUROPE (100%).
Directors
According to the 2026 annual accounts
Tadashi Ninomiya
Director
since 2026
Kurt Troch
Director
since 2026
Koji Aoki
Director
since 2022
since 2022
Managing director · represented by Koen Dewaele
since 2012 · until 2026
Goki Ishikawa
Director
since 2022 · until 2026
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 6
9052 Gent
Technologiepark-Zwijnaarde 94
9052 Gent
Active since 19 September 2011
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
adxneurosciences.com
Registered
2011-06-25
Registrar
Ascio Technologies, Inc
Expires
2026-06-25
Website info
Features
Security
Network
Details
- Company number
- 0839.400.980
- VAT number
- BE 0839.400.980
- Registered office
- Technologiepark-Zwijnaarde 6, 9052 Gent
- Names & denominations
- ADx NeuroSciences
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 September 2011
- Peppol
- Active · Active since 27 Mar 2026
- Contact
- adxneurosciences.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied